CN102648195B - 新的螺哌啶化合物 - Google Patents

新的螺哌啶化合物 Download PDF

Info

Publication number
CN102648195B
CN102648195B CN201080054116.3A CN201080054116A CN102648195B CN 102648195 B CN102648195 B CN 102648195B CN 201080054116 A CN201080054116 A CN 201080054116A CN 102648195 B CN102648195 B CN 102648195B
Authority
CN
China
Prior art keywords
compound
compounds
mmol
mixture
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080054116.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102648195A (zh
Inventor
C·哈姆杜希
J·P·莱恩斯瓦拉
P·麦提
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102648195(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102648195A publication Critical patent/CN102648195A/zh
Application granted granted Critical
Publication of CN102648195B publication Critical patent/CN102648195B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4747Quinolines; Isoquinolines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201080054116.3A 2009-11-30 2010-11-19 新的螺哌啶化合物 Expired - Fee Related CN102648195B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26518109P 2009-11-30 2009-11-30
US61/265,181 2009-11-30
PCT/US2010/057359 WO2011066183A1 (en) 2009-11-30 2010-11-19 Novel spiropiperidine compounds

Publications (2)

Publication Number Publication Date
CN102648195A CN102648195A (zh) 2012-08-22
CN102648195B true CN102648195B (zh) 2015-01-07

Family

ID=43384775

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080054116.3A Expired - Fee Related CN102648195B (zh) 2009-11-30 2010-11-19 新的螺哌啶化合物

Country Status (26)

Country Link
US (1) US8822486B2 (enExample)
EP (1) EP2507228B1 (enExample)
JP (1) JP5709889B2 (enExample)
KR (1) KR101410103B1 (enExample)
CN (1) CN102648195B (enExample)
AR (1) AR078948A1 (enExample)
AU (1) AU2010324987B2 (enExample)
BR (1) BR112012012903A2 (enExample)
CA (1) CA2781292C (enExample)
CL (1) CL2012001321A1 (enExample)
CR (1) CR20120296A (enExample)
DO (1) DOP2012000139A (enExample)
EA (1) EA020507B1 (enExample)
EC (1) ECSP12011930A (enExample)
ES (1) ES2526568T3 (enExample)
GT (1) GT201200164A (enExample)
IL (1) IL219594A0 (enExample)
MA (1) MA33840B1 (enExample)
MX (1) MX2012006233A (enExample)
NZ (1) NZ600203A (enExample)
PE (1) PE20121474A1 (enExample)
PH (1) PH12012501052A1 (enExample)
TN (1) TN2012000248A1 (enExample)
TW (1) TW201141866A (enExample)
WO (1) WO2011066183A1 (enExample)
ZA (1) ZA201203055B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
PE20121639A1 (es) 2009-12-25 2012-12-02 Mochida Pharm Co Ltd Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
CA2813639A1 (en) 2010-10-08 2012-04-12 Mochida Pharmaceutical Co. Ltd. Cyclic amide derivative
AU2012248629A1 (en) 2011-04-27 2013-11-28 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxyisothiazole 1-oxide derivative
CA2834465A1 (en) 2011-04-28 2012-11-01 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
US10118922B2 (en) * 2013-03-14 2018-11-06 Janssen Pharmaceutica Nv GPR120 agonists for the treatment of type II diabetes
AP2016009176A0 (en) 2013-11-14 2016-04-30 Cadila Healthcare Ltd Novel heterocyclic compounds
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN111712494A (zh) 2018-02-13 2020-09-25 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN110590767B (zh) * 2019-08-29 2021-10-08 南方科技大学 一种合成amg837的方法
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
BR112022017039A2 (pt) 2020-02-28 2022-11-16 Kallyope Inc Agonistas de gpr40
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ,インク. Ampkアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
KR20050120773A (ko) 2003-04-04 2005-12-23 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 작용제로서의 아실화스피로피페리딘 유도체
CA2544602A1 (en) 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
BRPI0508098A (pt) * 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
ATE429426T1 (de) * 2004-09-07 2009-05-15 Banyu Pharma Co Ltd Carbamoylsubstituiertes spiro-derivat
AU2007275931B2 (en) * 2006-07-19 2011-06-16 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
RU2009124419A (ru) * 2006-12-29 2011-02-10 Ф. Хоффманн-Ля Рош Аг (Ch) Азаспиропроизводные
JP2010524932A (ja) * 2007-04-16 2010-07-22 アムジエン・インコーポレーテツド 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質
AU2008314933B2 (en) * 2007-10-26 2013-05-02 Japan Tobacco Inc. Spiro-ring compound and use thereof for medical purposes
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament

Also Published As

Publication number Publication date
EA020507B1 (ru) 2014-11-28
KR20120088770A (ko) 2012-08-08
KR101410103B1 (ko) 2014-06-25
TW201141866A (en) 2011-12-01
JP5709889B2 (ja) 2015-04-30
PE20121474A1 (es) 2012-11-05
ZA201203055B (en) 2013-09-25
MA33840B1 (fr) 2012-12-03
ES2526568T3 (es) 2015-01-13
IL219594A0 (en) 2012-06-28
CA2781292C (en) 2014-04-22
MX2012006233A (es) 2012-07-03
PH12012501052A1 (en) 2013-02-04
CR20120296A (es) 2012-07-16
CN102648195A (zh) 2012-08-22
AR078948A1 (es) 2011-12-14
AU2010324987B2 (en) 2014-01-30
WO2011066183A1 (en) 2011-06-03
JP2013512277A (ja) 2013-04-11
ECSP12011930A (es) 2012-07-31
NZ600203A (en) 2013-09-27
CA2781292A1 (en) 2011-06-03
EP2507228A1 (en) 2012-10-10
EA201290416A1 (ru) 2012-11-30
US8822486B2 (en) 2014-09-02
US20120220616A1 (en) 2012-08-30
GT201200164A (es) 2014-02-27
CL2012001321A1 (es) 2013-11-15
TN2012000248A1 (en) 2013-12-12
EP2507228B1 (en) 2014-11-05
DOP2012000139A (es) 2012-08-15
AU2010324987A1 (en) 2012-07-26
BR112012012903A2 (pt) 2017-03-01

Similar Documents

Publication Publication Date Title
CN102648195B (zh) 新的螺哌啶化合物
KR101570624B1 (ko) 당뇨병의 치료에 유용한 신규 1,2,3,4-테트라히드로퀴놀린 유도체
US8383642B2 (en) Spiropiperidine compounds
RU2650506C2 (ru) Агонист рецептора gpr40, способы его получения и фармацевтические композиции, содержащие его в качестве активного ингредиента
JP5524091B2 (ja) エストロゲン関連受容体モジュレータ化合物及びその使用
KR20080109933A (ko) Hdl-c의 증가, ldl-c의 감소 및 콜레스테롤의 감소에 사용되는 ppar-델타 효능제로서의 벤조아제핀-옥시-아세트산 유도체
CA2587207A1 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2010006496A1 (zh) 用作雌激素相关受体调节剂的化合物及其应用
WO2022218440A1 (zh) Fxr调节剂及其制备方法、药物组合物和用途
PT1539746E (pt) Compostos de ácido 1h-indol-5-propiónico, substituído em n, como agonistas de ppar (receptores activados dos proliferadores de peroxissoma), úteis para o tratamento de diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150107

Termination date: 20161119